New Haven, Connecticut 06511

  • Healthy


This study will compare the plasma pharmacokinetics of a single 125mg oral dose of palbociclib in the presence and absence of rifampin-mediated enzyme induction in a fixed-sequence two-period study.


Inclusion Criteria: - Healthy males or females of non-childbearing potential - body mass index between 17.5-30.5 kg/m2 with a total body weight greater than 50kg Exclusion Criteria: - Evidence or history of any clinically significant physiologic, psychological, or medical conditions - a positive drug screen or alcohol breath test - a baseline ECG demonstrating a QTc>450msecs or a QRS interval >120msecs



Primary Contact:

Study Director
Pfizer Call Center

Pfizer Call Center
Phone: 1-800-718-1021

Backup Contact:


Location Contact:

New Haven, Connecticut 06511
United States

There is no listed contact information for this specific location.

Site Status: Recruiting

Data Source:

Date Processed: September 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.